De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

NCT00328770 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Liver Carcinoma

Interventions

DRUG: Sirolimus

Sponsor

University of Alberta